Researching the Topical Issues of Competence Approach in Pharmaceutical Education

The article is aimed at examining the emergence of a competence approach in higher pharmaceutical education due to the need to bring program requirements closer to the future specialist, society’s requests and the necessities of personal practical professional activity. The problems inherent in the development of professional training of specialists in the pharmaceutical industry in Ukraine are generalized. In particular, the growing need for the development of the pharmaceutical education system and insufficient attention to this sphere at both the State and local levels; imperfection of the regulatory framework for the professional training of specialists in the pharmaceutical industry; lack of foreign experience in professional training of specialists in the pharmaceutical industry. Etiology and interpretation of the concept of «competence» are studied. The lack of a unanimous approach to understanding the concept of «competence approach in education» is defined, various authors’ approaches to its content are explored. The reasons for the relevance of higher education development on the basis of competence orientation are determined. The problematic issues of the competence approach in the process of developing the higher education standards are researched, since pharmaceutical education cannot be separated from the strategic tasks of reforming the content of the educational process in Ukraine. Prospects for further research in this direction are the substantiation of methodological principles and organizational mechanisms for the formation of competence standards as a leading vector in the modernization of higher pharmaceutical education

Features of prevention of patients from ischemic heart disease combined with hypertension diasease

Ключовим напрямком у вирішенні питань зниження смертності в Україні від серцево-судинних за- хворювань є розробка та впровадження профілактичних заходів, контролю ведення пацієнтів, боротьба з нон- комплаєнтністю, створення доступних центрів здоров'я в поліклініках. Низька прихильність до лікування небезпечна з багатьох причин. По-перше, це загроза розвитку серйозних ускладнень, по-друге, прогресування захворювання, і як наслідок рання інвалідизація і смертність працездатного і соціально активного населення

Poltava bishophit in rehabilitation of patients with arterial hypertension

Застосування електрофорезу бішофіту Полтавського показано як на амбулаторному так і на стаціонарному етапах реабілітації пацієнтів з артеріальною гіпертензією

The level of systemic inflammation and the state of central hemodynamics in patients with coronary heart disease with metabolic syndrome

Metabolic syndrome (MS) is one of the possible risk factors for coronary heart disease (CHD) [2,7]. Meanwhile, cardiovascular disease, and first and foremost, CHD, is one of the leading causes of death in developed countries of the world [1,8]. The prognosis for patients with coronary heart disease depends, predominantly, on the progression of coronary atherosclerosis (CA). Clinical significance of MS is determined by its important prognostic value in the development of cardiovascular diseases (CVD), and in particular, CHD, due to disturbance of the function of endothelial and smooth muscle cells of the vessels, local intravascular inflammation, increased platelets function and thrombosis [4,8]. The achievement of recent years is the concept as to the important role of chronic systemic inflammation (CSI) and insulin resistance (IR) in the pathogenesis of CA and CHD, which is especially relevant for MS patients [3, 8, 9]

Evaluation of indicators of endothelial dysfunction and intracardiac hemodynamics of the left ventricle in patients with chronic pulmonary heart bronchopulmonary genesis of comorbidity with essential arterial hypertension

Chronic obstructive pulmonary disease (COPD) is the main cause of progression chronic pulmonary heart (CPH), it is a serious worldwide problem. The combination of COPD with essential arterial hypertension (EAH) ranges from 4 to 27.7% with increasing age

Atomic force microscopy of layer-doped triglycine sulfate ferroelectric crystals

This work was supported by the Ministry of Science and Higher Education within the State assignment FSRC «Crystallography and Photonics» RAS

Субарахноидальные кровоизлияния. Соврeменный взгляд на интенсивную терапию

The objective: to analyze the latest data on the management of patients with subarachnoid hemorrhage (SAH).Results: nimodipine is the only drug that possesses evidence-based efficacy to prevent and treat vasospasm. However, there are cases of refractory vasospasm. Furthermore, there are cases of delayed cerebral ischemia without angiographically detected vasospasm. This article describes the diagnostic, classification of the severity of SAH, the dependence of outcomes on the timing of surgical interventions and intensive care (volemia, glycemia, sodium, hemoglobin level, and optimal values of systolic blood pressure), the results of research on the use of drugs and methods potentially effective for the prevention and treatment of cerebral vasospasm.Цель обзора: проанализировать современную информацию на тему ведения пациентов с субарахноидальными кровоизлияниями (САК).Результат: доказанным препаратом в отношении профилактики и лечения вазоспазма является нимодипин, однако встречаются случаи вазоспазма, рефрактерного к данной терапии, а также случаи развития отсроченной церебральной ишемии в отсутствие вазоспазма. В статье отражены принципы диагностики, классификации тяжести САК, зависимость исходов от сроков оперативных вмешательств и интенсивной терапии (волемия, поддержание уровня гликемии, натрия, гемоглобина, оптимальные значения систолического артериального давления), результаты исследований по применению препаратов и методов, потенциально эффективных для профилактики и лечения церебрального вазоспазма на фоне САК

The level of systemic inflammation and the state of central hemodynamics in patients with coronary heart disease

Materials and methods. An open clinical trial was conducted. 230 patients with CHD were examined: stable angina pectoris, II FC, CH 0-I (119 men and 111 women aged 57 + 8.3 years) and 30 healthy subjects (control group). The criteria for inclusion in the study were the age of men and women (40-75 years), the presence of CHD: exertional angina of II FC in the absence of destabilization of the course for at least two months, the informed consent of the patient to participate in the study. The exclusion criteria were the presence of chronic heart failure higher than stage I, high blood pressure, complications of cardiac rhythm and conduction disorders, rheumatism, cancer, anemia, diabetes mellitus, renal and hepatic insufficiency. To achieve the aim of the research, patients’ blood was tested for levels of IL-1β and TNFα by the immune enzyme method; fibrinogen (FG) plasma levels – by weight method and echocardiography (echo) [7]. The global contractile ability of LV was estimated by the stroke volume (SV), the ejection fraction (EF), and the velocity of the blood flow (v) in the external path (EP) of the LV. The diastolic function of LV was investigated by recording the transmitral blood flow rates by the ratio of the velocities of the early (E) and late (L) diastolic filling of the LV (E / A), the delay time of early diastolic filling of the LV (DT) and the time of isovolumic LV relaxation (IVRT) [7]